CO6480963A2 - Aptamero para quimasa y su uso - Google Patents

Aptamero para quimasa y su uso

Info

Publication number
CO6480963A2
CO6480963A2 CO11180116A CO11180116A CO6480963A2 CO 6480963 A2 CO6480963 A2 CO 6480963A2 CO 11180116 A CO11180116 A CO 11180116A CO 11180116 A CO11180116 A CO 11180116A CO 6480963 A2 CO6480963 A2 CO 6480963A2
Authority
CO
Colombia
Prior art keywords
aptamer
complex
chimase
substance
different
Prior art date
Application number
CO11180116A
Other languages
English (en)
Inventor
Yoshikazu Nakamura
Ling Jin
Satoko Yamazaki
Hisako Ikeda
Masahiro Muraguchi
Original Assignee
Ribomic Inc
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc, Otsuka Pharma Co Ltd filed Critical Ribomic Inc
Publication of CO6480963A2 publication Critical patent/CO6480963A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21039—Chymase (3.4.21.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan un aptámero unido a quimasa para inhibir la actividad de quimasa; un aptámero que contiene una secuencia de nucleótidos representada porX1GAUAGAN1N2UAAX2 en donde X1 y X2 son iguales o diferentes y cada uno es A o G, y N1 y N2 son iguales o diferentes y cada uno es A, G, C, U o T; un complejo que contiene el aptámero y una sustancia funcional (por ejemplo, sustancia de afinidad, sustancia para marcación, enzima, medio de aplicación del fármaco, fármaco y similares); un agente farmacéutico o un reactivo que contiene el aptámero o complejo; métodos de detección y purificación de la quimasa usando el aptámero o complejo y similares.
CO11180116A 2009-06-11 2011-12-28 Aptamero para quimasa y su uso CO6480963A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009140585 2009-06-11

Publications (1)

Publication Number Publication Date
CO6480963A2 true CO6480963A2 (es) 2012-07-16

Family

ID=43308969

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11180116A CO6480963A2 (es) 2009-06-11 2011-12-28 Aptamero para quimasa y su uso

Country Status (20)

Country Link
US (1) US9012420B2 (es)
EP (1) EP2441833A4 (es)
JP (1) JP5810356B2 (es)
KR (1) KR20120028973A (es)
CN (1) CN102459588B (es)
AR (1) AR077049A1 (es)
AU (1) AU2010259549B2 (es)
BR (1) BRPI1010859A2 (es)
CA (1) CA2764472A1 (es)
CO (1) CO6480963A2 (es)
IL (1) IL216865A0 (es)
MX (1) MX2011013374A (es)
MY (1) MY177984A (es)
NZ (1) NZ597269A (es)
RU (1) RU2579667C2 (es)
SG (1) SG176723A1 (es)
TW (1) TWI532842B (es)
UA (1) UA107663C2 (es)
WO (1) WO2010143714A1 (es)
ZA (1) ZA201109372B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2701723B1 (en) 2011-04-28 2017-08-30 Mayo Foundation For Medical Education And Research Dna aptamers for promoting remyelination
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
US9567589B2 (en) 2011-09-28 2017-02-14 Ribomic Inc. NGF aptamer and application thereof
JP6041288B2 (ja) * 2012-02-13 2016-12-07 国立大学法人山口大学 ホスホランバン標的修飾ｒｎａアプタマー
WO2019093497A1 (ja) * 2017-11-09 2019-05-16 株式会社リボミック Ａｄａｍｔｓ５に対するアプタマー及びその使用
WO2019107532A1 (ja) 2017-11-30 2019-06-06 株式会社リボミック キマーゼに対するアプタマー及びその使用
US12037590B2 (en) 2018-12-06 2024-07-16 Mayo Foundation For Medical Education And Research Short DNA aptamers and methods for promoting remyelination
WO2021006305A1 (ja) * 2019-07-08 2021-01-14 株式会社リボミック ＴＧＦ－β１に対するアプタマー及びその使用
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
CN112362626B (zh) * 2020-11-11 2021-08-27 河南农业大学 正电性Ag@Au核壳结构纳米粒子在核酸酶活性检测中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
DK0533838T3 (da) 1990-06-11 1998-02-23 Nexstar Pharmaceuticals Inc Nukleinsyreligander
EP1683871B1 (en) 1992-09-29 2011-08-03 Gilead Sciences, Inc. Nucleic acid ligands and methods for producing the same
EP1793006A3 (en) 1993-09-08 2007-08-22 Gilead Sciences, Inc. Nucleic acid ligands and improved methods for producing the same
KR20010108519A (ko) 2000-02-22 2001-12-07 도리이 신이치로 키마제 억제제를 유효성분으로 하는 선유증의 예방 또는치료약
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1766042A2 (en) 2004-05-21 2007-03-28 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with chymase (cma1)
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease

Also Published As

Publication number Publication date
CA2764472A1 (en) 2010-12-16
EP2441833A4 (en) 2013-03-20
US9012420B2 (en) 2015-04-21
EP2441833A1 (en) 2012-04-18
AR077049A1 (es) 2011-07-27
SG176723A1 (en) 2012-01-30
IL216865A0 (en) 2012-02-29
US20120165401A1 (en) 2012-06-28
UA107663C2 (ru) 2015-02-10
WO2010143714A1 (ja) 2010-12-16
TW201103983A (en) 2011-02-01
JP5810356B2 (ja) 2015-11-11
AU2010259549A1 (en) 2012-01-19
NZ597269A (en) 2012-12-21
BRPI1010859A2 (pt) 2016-04-05
ZA201109372B (en) 2013-02-27
MX2011013374A (es) 2012-02-21
TWI532842B (zh) 2016-05-11
CN102459588B (zh) 2015-04-01
KR20120028973A (ko) 2012-03-23
RU2012100248A (ru) 2013-07-20
JPWO2010143714A1 (ja) 2012-11-29
MY177984A (en) 2020-09-28
RU2579667C2 (ru) 2016-04-10
AU2010259549B2 (en) 2015-10-01
CN102459588A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
CO6480963A2 (es) Aptamero para quimasa y su uso
EP4219745A3 (en) Spatially encoded biological assays using a microfluidic device
BRPI0917644A2 (pt) sistema transportador para agentes biológicos contendo compostos de organo-silício e usos do mesmo.
BR112014005205A2 (pt) métodos para etiquetar bibliotecas codificadas com dna
WO2010091246A3 (en) Burstable liquid packaging and uses thereof
BR112013025758A2 (pt) monitoramento de misturas de amplificação de recombinase polimerase
WO2014005125A3 (en) Fluorescent compounds and uses thereof
BR112012020251A2 (pt) dispositivo de análise para a aquisição de amostra, tratamento e reação
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
MX336195B (es) Sistema de tiempo de ejecucion.
BRPI0720153A8 (pt) Composições e artigos que contêm uma matriz de polímero reticulada e um líquido ativo imobilizado assim como processos de utilização dos mesmos
GB201013767D0 (en) Identification of ligands and their use
CR20110463A (es) Compuesto de anillo fusionado y su uso
BRPI0812771A2 (pt) Método para a detecção e diagnóstico in vitro de uma infecção por um microorganismo, conjunto de reagentes para a realização do método de detecção .
BR112015006273A2 (pt) ''método de prognóstico, kit que compreende reagentes, agente quimioterápico citotóxico terapêutico, uso de um agente quimioterápico citotóxico terapêutico, sistema para prognóstico de sobrevivência global e meio legível por computador''
BR112016017398A2 (pt) Material de proteína imobilizado, carreador, métodos para preparação de um material de proteína imobilizado e para catalisação de um reação, e, uso do material de proteína imobilizado
BRPI0820365A2 (pt) Método, sistema, e, mídia de armazenamento legível por computador.
WO2018052464A8 (en) METHODS AND SYSTEMS FOR MULTIPLEX TESTING
WO2011142781A3 (en) Pore-limit electrophoresis (ple) microchannel assays
SG10201407036YA (en) Markers of Endothelial Progenitor Cells and Uses Thereof
BR112013000340A2 (pt) anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica
BR112013012866A2 (pt) sistema de computador, método, e, meio legível por computador não transitório
BR112014032916A2 (pt) anticorpos anti-fármacos e usos destes para o monitoramento de fármaco

Legal Events

Date Code Title Description
FG Application granted